This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Mon, 06/10/2024 - 17:58 June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial tricuspid clip procedure in the Carolinas, performed in May at Atrium Health Carolinas Medical Center.
Traditionally, cardiothoracic surgeons have repaired or replaced the tricuspid valve during open-heartsurgery and only when absolutely necessary; such surgeries are complex and risky. Catheter-based procedures offer an alternative for patients who are not candidates for open-heartsurgery.
Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heartvalve, for which more than 1.6 Abbott has announced U.S million people in the U.S. are estimated to be affected. The device has already been used to treat more than 10,000 people with TR. 10.21037/cdt.2019.09.11.
Tricuspid regurgitation (TR) is a common and serious disease for which openheartsurgery and symptomatic pharmacologic treatment are the current standard treatment options. Owing to high mortality risk, access to openheartsurgery is severely restricted and is not considered an option for most patients with TR.
Barr’s death at 39 from sudden cardiac arrest was caused by mitral valve prolapse—a heartvalve defect that can affect the heart’s ability to pump blood. In the past, heart surgeons corrected a faulty mitral valve by replacing it with an artificial one during open-heartsurgery.
About Aortic Stenosis Aortic valve stenosis - or aortic stenosis - is a type of heartvalve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully.
Traditionally, cardiothoracic surgeons have repaired or replaced the tricuspid valve during open-heartsurgery and only when absolutely necessary; such surgeries are complex and risky. Catheter-based procedures offer an alternative for patients who are not candidates for open-heartsurgery.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content